ClinicalTrials.gg
Active, not recruitingNCT06508021ANDECALUpdated Nov 5, 2026

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

A Phase 2/3 interventional study of Andecaliximab and Placebo in Fibrodysplasia Ossificans Progressiva, sponsored by Ashibio Inc. Active, not recruiting at 3 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Ashibio Inc · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Myositis Ossificans with a site in United States — 4 open to participants now, 6 under way, 2 of them phase 3. Myositis Ossificans · United States.

Planned enrollment
4th of 12
92 · median 60
Started
2024
with 1 other
Phase 2/3
Only one
of the 19
Registered
18th of 19
by date
Lead sponsor
1 of 19
Ashibio Inc

Among the 19 studies in Myositis Ossificans with a site in United States, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 2/3, and was the 18th registered.

Myositis Ossificans

24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.

Browse Myositis Ossificans studies →

Open to participants now

4 of the 19 studies in Myositis Ossificans with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Myositis Ossificans studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myositis Ossificans with a site in United States, or all of them as a file.
02

Study summary

This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP.

The study is looking at several research questions, including:

  • Safety of andecaliximab in participants with FOP
  • Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; HO)
  • Whether andecaliximab reduces the number or severity of flare-ups
  • Pharmacokinetics/pharmacodynamics (PK/PD): How much study drug is in your blood at different times and its impact on blood biomarker(s)
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Read the detailed description

The ASH-FOP-201 Study consists of 2 parts: Part 1 is a Lead-in Study to assess safety, PK/PD and preliminary efficacy; Part 2 is the Main Study, a Phase 2/3 randomized, double-blind, placebo-controlled trial.

Part 1 is composed of Part 1a, a Na18F positron emission tomography (PET)/computed tomography, less head (CT) Study in up to 6 participants age ≥ 15 years, and Part 1b, a flare-up Study in up to 6 participants ≥ 12 years of age. Participants enrolled in Part 1 will be randomized to one of two dose levels for 13 weeks. Participants in Part 2 will be randomized to one of two dose levels of drug vs. placebo during the 52 week trial. All participants in Part 1 or Part2 will receive study drug in the extension period of the trial.

03

Conditions studied

  • Fibrodysplasia Ossificans Progressiva

Keywords

  • Myositis Ossificans
  • Ossification, Heterotopic
  • Hallux Valgus
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinase 9
  • Inflammation
  • Activin A receptor, type I protein, human
  • ALK-2 protein, human
  • ACVR1 protein, human
  • Muscle, Skeletal
  • Myositis
  • Muscular diseases
  • Musculoskeletal diseases
  • Flare
  • Flare-ups
  • ANDECAL
  • Heterotopic bone
  • Ectopic bone
  • Munchmeyer's Disease
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Part 1a, 1b, and 2):

  1. Participant and/or guardian able and willing to give and/or assent as applicable, and willing to adhere to the visits schedule and study procedures.
  2. Clinical diagnosis of FOP including congenital malformation(s) consistent with FOP (e.g., of the great toes), and either episodic soft tissue swelling consistent with an FOP flare-up and/or progressive HO.

4. CAJIS score of ≤19. 5. Disease activity within 1 year of screening visit. Disease activity is defined as physician confirmed flare-up like symptoms or clinical progression including newly identified HO or worsening joint function.

6. Able to understand, undergo, and perform all protocol related procedures, including low-dose WBCT-LH scan without sedation. Assistance from a caregiver is allowed.

7. Agree to provide access to all relevant current and historical medical records (including radiographs or radiographic records) and growth records.

Inclusion Criteria (Part 1a only):

  1. Male or female ≥ 15 years of age.
  2. Serum creatinine ≤ for age.
  3. No open growth plates on bilateral PA hand/wrist or AP knee films at baseline
  4. Able to receive IV radiotracer [both IV access and no history of a reaction to radiotracer].
  5. No use of bisphosphonates or bone active agent within the past year.
  6. At least 1 active HO lesion at baseline per Na18F PET/CT

Additional inclusion criteria apply including those listed above for all parts of the study.

Inclusion Criteria (Part 1b only):

  1. Male or female ≥12 years of age.
  2. History of multiple flare-up episodes within the past 6 months (to be reviewed and confirmed as qualifying by the PI together with the Sponsor). Qualifying flare-up episodes include any of the following:

    • At least 3 qualifying flare-ups in the past 6 months each with continuous symptoms for at least 1 week
    • Migratory flare-up swellings across the back
    • Multiple flare-up episodes the sum of which lasted at least 21 days The timing of the individual flare-ups can be overlapping; they may be ongoing at the time of enrollment or resolved.
  3. The qualifying flare-ups must involve at least 2 of the following flare-up symptoms:

    • Pain
    • Soft tissue swelling
    • Warmth
    • Redness
    • Joint stiffness
    • Decreased range of motion

Additional inclusion criteria apply including those listed above for all parts of the study.

Inclusion Criteria (Part 2 only):

  1. Initial enrollment age requirement is ≥12 years
  2. Enrollment may be extended to participants ≥6 years of age after safety in adult and participants age 12-17 years has been established.
  3. Enrollment of participants ≥2 to \<6 years of age will commence after safety in adult and participants ≥6 years of age has been established.

Additional inclusion criteria apply including those listed above for all parts of the study.

Exclusion Criteria:

  1. Body weight \<10kg
  2. Known non-healed fracture at time of Study Day 1.
  3. Planned surgery within the timeframe of the study duration or still recovering from recent surgery.
  4. Respiratory compromise that requires use of supplemental oxygen.
  5. Participant has

    • Known monogenic disorder other than FOP.
    • Bone or mineral disorder unrelated to FOP.
  6. (within the past 5 years, except non-melanoma skin cancer, cervical carcinoma in situ, or ductal carcinoma in situ [DCIS]).
  7. Known active infection (including fungal, bacterial, mycobacterial, or viral infection including COVID19)
  8. Uncontrolled hypoparathyroidism or hyperparathyroidism.
  9. Per participant report or chart review (no testing required): Uncontrolled hyperthyroidism
  10. Use of the following medication:

    • Systemic with a prednisone equivalent of >10mg/day within 1 week of Study Day 1. If the participant requires chronic use of >10mg/day prednisone equivalent of corticosteroids, eligibility will be discussed with the Sponsor.
    • NSAIDs of higher than doses recommended by the May 2022 ICCFOP guidelines within 1 week of Study Day 1. If the participant requires chronic use of NSAIDs at doses higher than those recommended by the May 2022 ICCFOP guidelines doses, eligibility will be discussed with the Sponsor.
    • Current or chronic use of tetracycline drugs (e.g., tetracycline, demeclocycline, doxycycline, or minocycline).
  11. Chronic use of any of unproven therapies for FOP.
  12. Palovarotene

    • Within 1 month of Study Day 1 for all participants
    • Within 2 years of Study Day 1 for female participants \<8 years of age Or male participants \<10 years of age
  13. Treatment with another product within 5 half lives of last dose at the time of Study Day 1 or 1 month, whichever is longer.
  14. History of allergy or to andecaliximab or its .
  15. Significant current laboratory abnormalities
  16. Breastfeeding, pregnant, or planning pregnancy.
  17. Those of unwilling to agree to abstain from sexual activity that could result in pregnancy or unwillingness to use acceptable during the study and for 90 days after the last dose.
  18. Simultaneous participation in another clinical trial involving another investigational product.
  19. Significant medical condition or disability or biochemical or hematologic abnormalities that in the opinion of the Investigator would expose the participant to undue risk, prevent the conduct of study procedures, or confound the study results.

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Part 1a: PET/CT Study

    a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) Study to assess the impact of two dose levels of andecaliximab administered subcutaneously (SC), once-a-week (QW) in participants age ≥ 15 years, with FOP on a number of outcomes including Safety, Pharmacokinetic (PK) and pharmacodynamic (PD) and the change from baseline of Na18F uptake in HO lesions by PET/CT scan, and Patient Reported Outcomes (PROs).

    Drug: Andecaliximab

  • Experimental
    Part 1b: Flare-up Study

    a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) study to assess the impact of two dose levels of andecaliximab administered SC QW in participants ≥12 years of age with a recent history of frequent flare-up episodes on a number of outcomes including safety, PK/PD, and flare-up incidence and symptoms and PROs.

    Drug: Andecaliximab

  • Placebo comparator
    Part 2: Main Study

    1-year (52-week) double-blind (Investigator, participant, and sponsor all blinded), placebo-controlled study of andecaliximab Dose level A or B (or age adjusted) SC QW or placebo in pediatric and adult patients with FOP. The Main Study will enroll approximately 80 participants, randomized in a 1:1:1 ratio to andecaliximab Dose level A or B (or age adjusted) SC QW or placebo.

    Drug: Placebo · Drug: Andecaliximab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of New HO Lesions as Assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)]

    Low dose WBCT-LH (whole body CT less head) is used to create detailed images of soft tissues and bones.

    Time frame: Week 27 and 53

Secondary outcomes

  1. Percent change from baseline in Na18F standardized uptake value maximum (SUVmax) of up to 7 individual HO lesion(s) per participant active at baseline as assessed by Na18F PET/CT (Part 1a).

    SUV max is the SUV of the most intense voxel within a region of interest.

    Time frame: Week 14

  2. Change in HO volume over time as assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)] (Part 1a)

    Low dose WBCT-LH (whole body CT less head) is used to create detailed images of soft tissues and bones. In Part 1a, the WBCT-LH scan will be acquired as part of the PET/CT scan at baseline and Week 14.

    Time frame: Week 14

  3. Change in HO volume over time as assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)]

    Time frame: Week 27 and 53

  4. Number of days during which a flare-up is experienced by the participant as reported by the participant

    Flare-up defined as having at least two of the following symptoms: pain, soft tissue swelling, warmth, redness, joint stiffness, or decreased range of motion.

    Time frame: Week 14, 27 and 53

  5. Number of flare-ups as reported by the participant

    Time frame: Week 14, 27 and 53

  6. Number of flare-ups as reported by the participant and confirmed by the Principal Investigator

    Time frame: Week 14, 27 and 53

  7. Change in patient joint involvement as assessed by Investigator using Cumulative Analog Joint Involvement Scale (CAJIS)

    CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30.

    Time frame: Week 27 and 53

  8. Change in patient quality of life as assessed by the EuroQol 5 dimensions questionnaire with a 5-level scale (EQ-5D-5L)

    EQ-5D-5L measures: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.

    Time frame: Week 27 and 53

  9. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Number of participants with Treatment-Emergent Adverse Events (AE) (TEAEs), i.e., adverse events not present at baseline or exacerbation of a pre-existing condition during the on-treatment period will be reported.

    Time frame: Week 27 and 53

  10. Number of Participants With Serious Treatment-Emergent Adverse Events (Serious TEAEs)

    Number of participants with Serious Treatment-Emergent Adverse Events (AE) (TEAEs), i.e, required initial/prolonged in-patient hospitalization, death, life-threatening, persistent/significant disability/incapacity, congenital anomaly/birth defect, considered as a medically important event.

    Time frame: Week 27 and 53

  11. Number of Participants With TEAEs by Severity

    Severity of TEAEs will be graded as follows: Mild: Does not interfere in a significantly with functioning. Moderate: Causes some impairment of functioning but is not hazardous to health. Severe: Significant impairment or incapacitation; hazardous to one's health. Number of participants with TEAEs by severity will be reported.

    Time frame: Week 27 and 53

07

Study locations

3 sites
08

References and documents

Publications

  • Lounev V, Groppe JC, Brewer N, Wentworth KL, Smith V, Xu M, Schomburg L, Bhargava P, Al Mukaddam M, Hsiao EC, Shore EM, Pignolo RJ, Kaplan FS. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice. J Bone Miner Res. 2024 May 2;39(4):382-398. doi: 10.1093/jbmr/zjae029. PubMed 38477818 ↗
  • Wein MN, Yang Y. Actionable disease insights from bedside-to-bench investigation in fibrodysplasia ossificans progressiva. J Bone Miner Res. 2024 May 2;39(4):375-376. doi: 10.1093/jbmr/zjae044. No abstract available. PubMed 38644656 ↗

Individual participant data

Plan to share: Yes — Redacted Protocol and SAP will be made available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After completion of the Biologics License Applications (BLA) and all participants have completed the one year extension.

Access criteria: Not decided at this time

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Feb 2029, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Jul 18, 2024
StartActual
Oct 25, 2024
Primary completionEst.
Feb 4, 2029
CompletionEst.
Feb 4, 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06508021
Lead sponsor
Ashibio Inc
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Oct 25, 2024
Primary completion
Feb 4, 2029 (estimated)
Completion
Feb 4, 2029 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion